Posted on 17/06/2010 in Pharmaceutical Company Product News Ipsen has been granted a positive recommendation for its new haemophilia treatment OBI-1 to be granted European orphan drug status.
The company, in association with partner Inspiration Biopharmaceuticals, was issued with the positive opinion by the Committee for Orphan Medicinal Products of the European Medicines Agency.
Should the treatment receive orphan drug status, it would be granted a ten-year period of market exclusivity within Europe following its final marketing approval.
Ipsen now expects the European Commission to formally adopt the opinion later this year.
Jean-Luc Belingard, chairman and chief executive officer of Ipsen, said: "We are honoured that the Committee for Orphan Medicinal Products of the European Medicines Agency shares our view of the medical benefit provided by OBI-1 to the haemophilia community."
Last month, Ipsen published its financial results for the first quarter of 2010, reporting a 6.2 per cent year-on-year increase in drug sales for the three-month period.Other news stories from 17/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
